- Home
- HTFL vs HCM Comparison
HTFL vs HCM Comparison
Compare HTFL & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTFL | HCM |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HTFL | HCM |
|---|---|---|
| Price | $31.22 | $15.62 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $38.20 | $13.75 |
| AVG Volume (30 Days) | ★ 1.5M | 33.0K |
| Earning Date | 05-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.66 | $20.60 |
| Revenue Next Year | $23.55 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.13 | $13.06 |
| 52 Week High | $41.22 | $19.50 |
Technical Indicators
Market Signals| Indicator | HTFL | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 73.22 | 67.21 |
| Support Level | $28.86 | $14.69 |
| Resistance Level | $32.52 | $16.43 |
| Average True Range (ATR) | 1.52 | 0.45 |
| MACD | 0.55 | 0.07 |
| Stochastic Oscillator | 95.77 | 97.71 |
Price Performance
Historical ComparisonAbout HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.